Medpace (NASDAQ:MEDP) Issues Earnings Results

Medpace (NASDAQ:MEDP) posted its quarterly earnings data on Monday. The company reported $3.67 earnings per share for the quarter, beating the consensus estimate of $2.96 by $0.71, Zacks reports. Medpace had a net margin of 17.66% and a return on equity of 50.87%. Medpace updated its FY 2025 guidance to 11.930-12.690 EPS.

Medpace Stock Performance

Shares of NASDAQ:MEDP opened at $354.51 on Tuesday. The company has a 50 day moving average price of $343.88 and a two-hundred day moving average price of $349.52. The company has a market capitalization of $11.02 billion, a PE ratio of 31.04, a PEG ratio of 1.85 and a beta of 1.36. Medpace has a 52 week low of $302.01 and a 52 week high of $459.77.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Redburn Atlantic began coverage on shares of Medpace in a report on Monday, October 14th. They issued a “buy” rating and a $404.00 price target for the company. TD Cowen dropped their target price on Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. Robert W. Baird raised their price target on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. William Blair reissued an “outperform” rating on shares of Medpace in a report on Tuesday, October 22nd. Finally, Truist Financial cut their target price on shares of Medpace from $415.00 to $397.00 and set a “hold” rating on the stock in a research report on Monday, October 14th. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, Medpace presently has an average rating of “Hold” and a consensus price target of $381.44.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.